Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.
- Published in:
- Haemophilia, 2006, v. 12, p. 1, doi. 10.1111/j.1365-2516.2006.01359.x
- By:
- Publication type:
- Article
Works matching IS 13518216 AND DT 2006 AND VI 12
Results: 209
1
2
Basic aspects of bypassing agents.
- Published in:
- Haemophilia, 2006, v. 12, p. 48, doi. 10.1111/j.1365-2516.2006.01366.x
- By:
- Publication type:
- Article
3
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
- Published in:
- Haemophilia, 2006, v. 12, p. 8, doi. 10.1111/j.1365-2516.2006.01360.x
- By:
- Publication type:
- Article
4
Genetic risk factors for inhibitors to factors VIII and IX.
- Published in:
- Haemophilia, 2006, v. 12, p. 15, doi. 10.1111/j.1365-2516.2006.01361.x
- By:
- Publication type:
- Article
5
The epidemiology of factor VIII inhibitors.
- Published in:
- Haemophilia, 2006, v. 12, p. 23, doi. 10.1111/j.1365-2516.2006.01362.x
- By:
- Publication type:
- Article
6
Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
- Published in:
- Haemophilia, 2006, v. 12, p. 37, doi. 10.1111/j.1365-2516.2006.01364.x
- By:
- Publication type:
- Article
7
Characteristics of inhibitors in mild/moderate haemophilia A.
- Published in:
- Haemophilia, 2006, v. 12, p. 43, doi. 10.1111/j.1365-2516.2006.01365.x
- By:
- Publication type:
- Article
8
Immunological aspects of inhibitor development.
- Published in:
- Haemophilia, 2006, v. 12, p. 30, doi. 10.1111/j.1365-2516.2006.01363.x
- By:
- Publication type:
- Article
9
An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.
- Published in:
- Haemophilia, 2006, v. 12, p. 54, doi. 10.1111/j.1365-2516.2006.01367.x
- By:
- Publication type:
- Article
10
Prophylaxis in haemophilia patients with inhibitors.
- Published in:
- Haemophilia, 2006, v. 12, p. 67, doi. 10.1111/j.1365-2516.2006.01369.x
- By:
- Publication type:
- Article
11
Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
- Published in:
- Haemophilia, 2006, v. 12, p. 74, doi. 10.1111/j.1365-2516.2006.01370.x
- By:
- Publication type:
- Article
12
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
- Published in:
- Haemophilia, 2006, v. 12, p. 62, doi. 10.1111/j.1365-2516.2006.01368.x
- By:
- Publication type:
- Article
13
Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
- Published in:
- Haemophilia, 2006, v. 12, p. 87, doi. 10.1111/j.1365-2516.2006.01371.x
- By:
- Publication type:
- Article
14
Novel therapies for immune tolerance in haemophilia A.
- Published in:
- Haemophilia, 2006, v. 12, p. 94, doi. 10.1111/j.1365-2516.2006.01372.x
- By:
- Publication type:
- Article
15
Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
- Published in:
- Haemophilia, 2006, v. 12, p. 102, doi. 10.1111/j.1365-2516.2006.01373.x
- By:
- Publication type:
- Article
16
Urgent inhibitor issues: targets for expanded research.
- Published in:
- Haemophilia, 2006, v. 12, p. 107, doi. 10.1111/j.1365-2516.2006.01374.x
- By:
- Publication type:
- Article
17
Program Faculty.
- Published in:
- Haemophilia, 2006, v. 12, p. iii, doi. 10.1111/j.1365-2516.2006.01375_1.x
- Publication type:
- Article
18
Sponsorship and CME Credit.
- Published in:
- Haemophilia, 2006, v. 12, p. iv, doi. 10.1111/j.1365-2516.2006.01375_2.x
- Publication type:
- Article
19
CME Assessment Test and Activity Evaluation.
- Published in:
- Haemophilia, 2006, v. 12, p. v, doi. 10.1111/j.1365-2516.2006.01375_3.x
- Publication type:
- Article
20
Immune tolerance: critical issues of factor dose, purity and treatment complications.
- Published in:
- Haemophilia, 2006, v. 12, p. 81, doi. 10.1111/j.1365-2516.2006.01376.x
- By:
- Publication type:
- Article
21
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.
- Published in:
- Haemophilia, 2006, v. 12, p. 1, doi. 10.1111/j.1365-2516.2006.01359.x
- By:
- Publication type:
- Article
22
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
- Published in:
- Haemophilia, 2006, v. 12, p. 8, doi. 10.1111/j.1365-2516.2006.01360.x
- By:
- Publication type:
- Article
23
Genetic risk factors for inhibitors to factors VIII and IX.
- Published in:
- Haemophilia, 2006, v. 12, p. 15, doi. 10.1111/j.1365-2516.2006.01361.x
- By:
- Publication type:
- Article
24
The epidemiology of factor VIII inhibitors.
- Published in:
- Haemophilia, 2006, v. 12, p. 23, doi. 10.1111/j.1365-2516.2006.01362.x
- By:
- Publication type:
- Article
25
Immunological aspects of inhibitor development.
- Published in:
- Haemophilia, 2006, v. 12, p. 30, doi. 10.1111/j.1365-2516.2006.01363.x
- By:
- Publication type:
- Article
26
Inhibitor treatment in haemophilias A and B: inhibitor diagnosis.
- Published in:
- Haemophilia, 2006, v. 12, p. 37, doi. 10.1111/j.1365-2516.2006.01364.x
- By:
- Publication type:
- Article
27
Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
- Published in:
- Haemophilia, 2006, v. 12, p. 74, doi. 10.1111/j.1365-2516.2006.01370.x
- By:
- Publication type:
- Article
28
Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
- Published in:
- Haemophilia, 2006, v. 12, p. 87, doi. 10.1111/j.1365-2516.2006.01371.x
- By:
- Publication type:
- Article
29
FEIBA safety and tolerability profile.
- Published in:
- Haemophilia, 2006, v. 12, p. 14, doi. 10.1111/j.1365-2516.2006.01380.x
- By:
- Publication type:
- Article
30
Options for treating acute bleeds in addition to bypassing agents: extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics.
- Published in:
- Haemophilia, 2006, v. 12, p. 62, doi. 10.1111/j.1365-2516.2006.01368.x
- By:
- Publication type:
- Article
31
Prophylaxis in haemophilia patients with inhibitors.
- Published in:
- Haemophilia, 2006, v. 12, p. 67, doi. 10.1111/j.1365-2516.2006.01369.x
- By:
- Publication type:
- Article
32
Characteristics of inhibitors in mild/moderate haemophilia A.
- Published in:
- Haemophilia, 2006, v. 12, p. 43, doi. 10.1111/j.1365-2516.2006.01365.x
- By:
- Publication type:
- Article
33
Basic aspects of bypassing agents.
- Published in:
- Haemophilia, 2006, v. 12, p. 48, doi. 10.1111/j.1365-2516.2006.01366.x
- By:
- Publication type:
- Article
34
An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents.
- Published in:
- Haemophilia, 2006, v. 12, p. 54, doi. 10.1111/j.1365-2516.2006.01367.x
- By:
- Publication type:
- Article
35
Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development.
- Published in:
- Haemophilia, 2006, v. 12, p. 102, doi. 10.1111/j.1365-2516.2006.01373.x
- By:
- Publication type:
- Article
36
Author index.
- Published in:
- Haemophilia, 2006, v. 12, n. 6, p. 694, doi. 10.1111/j.1365-2516.2006.01391.x
- Publication type:
- Article
37
Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
- Published in:
- Haemophilia, 2006, v. 12, n. 4, p. 448, doi. 10.1111/j.1365-2516.2006.01297.x
- By:
- Publication type:
- Article
38
Novel therapies for immune tolerance in haemophilia A.
- Published in:
- Haemophilia, 2006, v. 12, p. 94, doi. 10.1111/j.1365-2516.2006.01372.x
- By:
- Publication type:
- Article
39
Urgent inhibitor issues: targets for expanded research.
- Published in:
- Haemophilia, 2006, v. 12, p. 107, doi. 10.1111/j.1365-2516.2006.01374.x
- By:
- Publication type:
- Article
40
Program Faculty.
- Published in:
- Haemophilia, 2006, v. 12, p. iii, doi. 10.1111/j.1365-2516.2006.01375_1.x
- Publication type:
- Article
41
Sponsorship and CME Credit.
- Published in:
- Haemophilia, 2006, v. 12, p. iv, doi. 10.1111/j.1365-2516.2006.01375_2.x
- Publication type:
- Article
42
Immune tolerance: critical issues of factor dose, purity and treatment complications.
- Published in:
- Haemophilia, 2006, v. 12, p. 81, doi. 10.1111/j.1365-2516.2006.01376.x
- By:
- Publication type:
- Article
43
CME Assessment Test and Activity Evaluation.
- Published in:
- Haemophilia, 2006, v. 12, p. v, doi. 10.1111/j.1365-2516.2006.01375_3.x
- Publication type:
- Article
44
The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor.
- Published in:
- Haemophilia, 2006, v. 12, p. 4, doi. 10.1111/j.1365-2516.2006.01379.x
- By:
- Publication type:
- Article
45
Considerations in the management of patients with haemophilia and inhibitors.
- Published in:
- 2006
- By:
- Publication type:
- Editorial
46
Dedication.
- Published in:
- 2006
- By:
- Publication type:
- Other
47
The use of FEIBA for surgery in patients with haemophilia and inhibitors.
- Published in:
- Haemophilia, 2006, v. 12, p. 20, doi. 10.1111/j.1365-2516.2006.01381.x
- By:
- Publication type:
- Article
48
FEIBA prophylaxis for patients with haemophilia and inhibitors.
- Published in:
- Haemophilia, 2006, v. 12, p. 26, doi. 10.1111/j.1365-2516.2006.01382.x
- By:
- Publication type:
- Article
49
The management of acquired haemophilia.
- Published in:
- Haemophilia, 2006, v. 12, p. 32, doi. 10.1111/j.1365-2516.2006.01383.x
- By:
- Publication type:
- Article
50
Identification of three FGA mutations in two Chinese families with congenital afibrinogenaemia.
- Published in:
- Haemophilia, 2006, v. 12, n. 6, p. 615, doi. 10.1111/j.1365-2516.2006.01320.x
- By:
- Publication type:
- Article